Andere Sprachen AegirBio AB

Aktien

A2P7ZC

SE0014401121

AEGIR

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:22:34 20.05.2024			% 5 Tage	% 1. Jan.
0.652 ^SEK	+10.51%		+34.99%	-44.27%

17.05.	AegirBio AB (publ) meldet Ergebniszahlen für das erste Quartal zum 31. März 2024	CI
09.04.	AegirBio unterzeichnet eine bedingte Vereinbarung über ein Darlehen von 45 Millionen SEK mit Atlas	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AegirBio AB Reports Earnings Results for the First Quarter Ended March 31, 2024	17.05.
AEGIRBIO study published in Multiple Sclerosis and Related Disorders journal	16.05.
AegirBio AB calls for payment of Tranche 1 of SEK 7.50 million and intends to carry out a directed set-off issue of 5,175,374 shares to Atlas Special Opportunities, LLC	13.05.
AEGIRBIO Receives Milestone Payment under RadX NIH	08.05.
AEGIRBIO AB ADVANCES FURTHER WITH "ACCESSIBILITY" MILESTONE COMPLETION IN RADx® TECH PROGRAM	30.04.
AegirBio Unit Begins Arbitration Proceedings vs Salofa for Breach of Contract	19.04.
AegirBio AB's subsidiary initiates arbitration against Salofa Oy	18.04.
AegirBio Signs Conditional Agreement for SEK45 Million Loan With Atlas	09.04.
AegirBio Chairman to Resign	09.04.
AegirBio's chairman has announced his intention to leave the board of directors	09.04.
AegirBio AB Announces Intention of Anders Ingvarsson to Resign as Board Member and Chairman	09.04.
AegirBio enters into a conditional agreement on a MSEK 45 loan facility with Atlas Special Opportunities and an agreement to amend the outstanding convertible bonds, subject to EGM approval	09.04.
AegirBio AB Enters into Conditional Agreement on a SEK 45 Million Loan Facility with Atlas Special Opportunities, LLC	09.04.
AegirBio AB Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
AegirBio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.03.
Aegirbio Expands Oral Health Scientific Advisory Board with Professor Iain L.C. Chapple	27.02.
AegirBio AB Announces the Appointment of Iain L. C. Chapple to the Scientific Advisory Board	27.02.
Renowned Gastroenterologist, Dr. Adam S. Cheifetz, Joins AegirBio's Scientific Advisory Board	24.01.
AegirBio AB Appoints Adam S. Cheifetz as Scientific Advisory Board	24.01.
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 5.00	20.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AegirBio AB

Aktien

A2P7ZC

SE0014401121

AEGIR

Andere Sprachen

Filter